Regulation: The FDA is overcautious on consumer genomics

Robert C Green and Nita A Farahany
Additional contact information
Robert C Green: Brigham and Women’s Hospital and Harvard Medical School, and the Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts.
Nita A Farahany: Nita A. Farahany is at the Duke University School of Law and the Duke Institute for Genome Sciences and Policy, Durham, North Carolina.

Nature, 2014, vol. 505, issue 7483, 286-287

Abstract: A US drug-agency clampdown is unwarranted without evidence of harm, say Robert C. Green and Nita A. Farahany.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/505286a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:505:y:2014:i:7483:d:10.1038_505286a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/505286a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().